In vitro and in vivo studies both confirm that BAF312@cRGD-CaP-NPs showed dramatically improved tumor targeting ability and can effectively improve the antitumor effect of BAF312 and inhibit tumor angiogenesis, which is mediated through the S1PR1/P-STAT3/VEGFA pathway. This evidence concerns the gene S1PR1 and neoplasm.